RxDoctor Payments Data

Calvin Brown, MD

Ophthalmology · Olive Branch, MSNPI 1578761011

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,540 of the $15,197 with a category attached, or 62.8%. Apellis Pharmaceuticals, Inc. accounts for 60.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $9,801 and has fallen 92.5% since, to $731 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,197in general payments, 2019–2025

Across 188 payments — averaging $80.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$9K
  • Alimera Sciences, Inc.$2K
  • Genentech USA, Inc.$802
  • AbbVie$644
  • Regeneron Healthcare Solutions, Inc.$424
  • Mallinckrodt Hospital Products Inc.$383
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$9,54063%
  • Travel & lodging$1021%
  • Food & beverage$5,22434%
  • Education$1001%
  • Gifts$190%
  • Entertainment$2121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,197 in reported general payments places this provider in the 90th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$2,073,800
Medicare patients
550
Services billed
19,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast11$15,492
Restasis MultidoseCyclosporine17$10,560
RestasisCyclosporine12$8,675
CombiganBrimonidine Tartrate/Timolol12$5,478
Prednisolone Acetate96$4,443
Ketorolac Tromethamine63$2,383
MoxifloxacinMoxifloxacin Hcl44$926
Latanoprost63$581
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis Multidose, Restasis, Combigan$644$24,71341 claims
Bausch & Lomb Americas Inc.Xiidra$33$15,49211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Olive Branch

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →